Get the latest news, insights, and market updates on MURA (Mural Oncology plc). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”), XRA 5 Corp. (“Sub”) and Mural announced on August 20, 2025 (the “Transaction Agreement”), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction Agreem Nov 26, 2025 - $MURA
Form 8.3
LONDON, November 26, 2025-- Ap27 Nov 26, 2025 - $MURA
Form 8.3
LONDON, November 25, 2025-- FORM 8.3 Nov 25, 2025 - $MURA
Form 8.3
LONDON, November 24, 2025-- FORM 8.3 Nov 24, 2025 - $MURA
Form 8.3
LONDON, November 21, 2025-- Ap27 Nov 21, 2025 - $MURA
Form 8.3
LONDON, November 20, 2025-- Ap27 Nov 20, 2025 - $MURA
Form 8.3
LONDON, November 19, 2025-- FORM 8.3 Nov 19, 2025 - $MURA
Form 8.3
LONDON, November 18, 2025-- FORM 8.3 Nov 18, 2025 - $MURA
Form 8.3
LONDON, November 17, 2025-- Ap27 Nov 17, 2025 - $MURA
Form 8.3
LONDON, November 14, 2025-- Ap27 Nov 14, 2025 - $MURA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.